The FDA decision on Dynavax Technologies Corp.’s (DVAX) HEPLISAV-B, a vaccine candidate for immunization against hepatitis B infection in adults ages 18 years of age and older, is expected on August 10, 2017.An FDA panel, on July 28, 2017, voted 12 to 1 that the safety data for HEPLISAV-B supports its approval. In the recent review, the panel was not asked to vote on the immunogenicity (efficacy) of the vaccine.In November 2012, the panel had voted 13 to one that HEPLISAV-B demonstrated immunogenicity (efficacy), but voted eight to five with one abstention that there was insufficient data to support its safety.HEPLISAV-B has been turned down twice by the FDA, i.e., in February 2013 and November 2016.It remains to be seen if the third time will be the charm. The FDA usually follows recommendations from its expert panels, although it is not required to do so.DVAX closed Friday's (July 28) trading at $9.25. In after-hours, the stock was up 80% to $16.65.